Difference between revisions of "Serous carcinoma of the endometrium"
Jump to navigation
Jump to search
(split -out) |
(→IHC) |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{ Infobox diagnosis | |||
| Name = {{PAGENAME}} | |||
| Image = Uterine serous carcinoma high mag.jpg | |||
| Width = | |||
| Caption = Serous carcinoma of the endometrium. [[H&E stain]]. | |||
| Synonyms = serous endometrial carcinoma, serous carcinoma of the uterus, uterine serous carcinoma, uterine papillary serous carcinoma | |||
| Micro = | |||
| Subtypes = | |||
| LMDDx = high-grade [[endometrioid endometrial carcinoma]], [[clear cell carcinoma of the endometrium]],[[Arias-Stella reaction]], [[serous carcinoma]] from elsewhere | |||
| Stains = | |||
| IHC = p16 +ve (strong), p53 +ve usu. (diffuse & strong > 50% ''or'' 75% of the tumour), Ki-67 "high", ER -ve, PR -ve | |||
| EM = | |||
| Molecular = | |||
| IF = | |||
| Gross = | |||
| Grossing = | |||
| Site = [[endometrium]] - see ''[[endometrial carcinoma]]'' | |||
| Assdx = | |||
| Syndromes = | |||
| Clinicalhx = usu. post-menopausal women | |||
| Signs = | |||
| Symptoms = | |||
| Prevalence = | |||
| Bloodwork = | |||
| Rads = | |||
| Endoscopy = | |||
| Prognosis = moderate-to-poor - dependent on stage | |||
| Other = | |||
| ClinDDx = | |||
| Tx = total hysterectomy + lymph node dissection | |||
}} | |||
'''Serous carcinoma of the endometrium''' is an aggressive type of [[endometrial carcinoma]] that typically afflicts post-menopausal women. | '''Serous carcinoma of the endometrium''' is an aggressive type of [[endometrial carcinoma]] that typically afflicts post-menopausal women. | ||
| Line 28: | Line 59: | ||
*[[Clear cell carcinoma of the endometrium]] - usually have less nuclear pleomorphism and less mitoses. | *[[Clear cell carcinoma of the endometrium]] - usually have less nuclear pleomorphism and less mitoses. | ||
*[[Arias-Stella reaction]]. | *[[Arias-Stella reaction]]. | ||
*Metastatic [[serous carcinoma]]. | |||
*[[Endometrium with psammoma bodies]] - no atypical cells. | |||
===Images=== | ===Images=== | ||
| Line 36: | Line 69: | ||
==IHC== | ==IHC== | ||
*p16 +ve<ref name=pmid17581420>{{Cite journal | last1 = Chiesa-Vottero | first1 = AG. | last2 = Malpica | first2 = A. | last3 = Deavers | first3 = MT. | last4 = Broaddus | first4 = R. | last5 = Nuovo | first5 = GJ. | last6 = Silva | first6 = EG. | title = Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. | journal = Int J Gynecol Pathol | volume = 26 | issue = 3 | pages = 328-33 | month = Jul | year = 2007 | doi = 10.1097/01.pgp.0000235065.31301.3e | PMID = 17581420 }}</ref> - should be strong. | *[[p16]] +ve<ref name=pmid17581420>{{Cite journal | last1 = Chiesa-Vottero | first1 = AG. | last2 = Malpica | first2 = A. | last3 = Deavers | first3 = MT. | last4 = Broaddus | first4 = R. | last5 = Nuovo | first5 = GJ. | last6 = Silva | first6 = EG. | title = Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. | journal = Int J Gynecol Pathol | volume = 26 | issue = 3 | pages = 328-33 | month = Jul | year = 2007 | doi = 10.1097/01.pgp.0000235065.31301.3e | PMID = 17581420 }}</ref> - should be strong. | ||
*p53 +ve<ref name=pmid19623034>{{Cite journal | last1 = Yemelyanova | first1 = A. | last2 = Ji | first2 = H. | last3 = Shih | first3 = IeM. | last4 = Wang | first4 = TL. | last5 = Wu | first5 = LS. | last6 = Ronnett | first6 = BM. | title = Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. | journal = Am J Surg Pathol | volume = 33 | issue = 10 | pages = 1504-14 | month = Oct | year = 2009 | doi = 10.1097/PAS.0b013e3181ac35f5 | PMID = 19623034 }}</ref> diffuse & strong > 50% ''or'' 75% of the tumour - depending on the paper one reads. | *p53 +ve<ref name=pmid19623034>{{Cite journal | last1 = Yemelyanova | first1 = A. | last2 = Ji | first2 = H. | last3 = Shih | first3 = IeM. | last4 = Wang | first4 = TL. | last5 = Wu | first5 = LS. | last6 = Ronnett | first6 = BM. | title = Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. | journal = Am J Surg Pathol | volume = 33 | issue = 10 | pages = 1504-14 | month = Oct | year = 2009 | doi = 10.1097/PAS.0b013e3181ac35f5 | PMID = 19623034 }}</ref> diffuse & strong > 50% ''or'' 75% of the tumour - depending on the paper one reads. | ||
**Subset is p53 -ve. | **Subset is p53 -ve. | ||
| Line 48: | Line 81: | ||
Notes: | Notes: | ||
*p16 +ve in tubal metaplasia.<ref name=pmid17429140>{{Cite journal | last1 = Horree | first1 = N. | last2 = Heintz | first2 = AP. | last3 = Sie-Go | first3 = DM. | last4 = van Diest | first4 = PJ. | title = p16 is consistently expressed in endometrial tubal metaplasia. | journal = Cell Oncol | volume = 29 | issue = 1 | pages = 37-45 | month = | year = 2007 | doi = | PMID = 17429140 }}</ref> | *[[p16]] +ve in tubal metaplasia.<ref name=pmid17429140>{{Cite journal | last1 = Horree | first1 = N. | last2 = Heintz | first2 = AP. | last3 = Sie-Go | first3 = DM. | last4 = van Diest | first4 = PJ. | title = p16 is consistently expressed in endometrial tubal metaplasia. | journal = Cell Oncol | volume = 29 | issue = 1 | pages = 37-45 | month = | year = 2007 | doi = | PMID = 17429140 }}</ref> | ||
*WT1 usu. -ve -- useful to differentiate from [[ovarian serous carcinoma]].<ref name=pmid21993272>{{Cite journal | last1 = Bárcena | first1 = C. | last2 = Oliva | first2 = E. | title = WT1 expression in the female genital tract. | journal = Adv Anat Pathol | volume = 18 | issue = 6 | pages = 454-65 | month = Nov | year = 2011 | doi = 10.1097/PAP.0b013e318234aaed | PMID = 21993272 }}</ref> | *WT1 usu. -ve -- useful to differentiate from [[ovarian serous carcinoma]].<ref name=pmid21993272>{{Cite journal | last1 = Bárcena | first1 = C. | last2 = Oliva | first2 = E. | title = WT1 expression in the female genital tract. | journal = Adv Anat Pathol | volume = 18 | issue = 6 | pages = 454-65 | month = Nov | year = 2011 | doi = 10.1097/PAP.0b013e318234aaed | PMID = 21993272 }}</ref> | ||
==Sign out== | |||
<pre> | |||
ENDOMETRIUM, BIOPSY: | |||
- SEROUS CARCINOMA, HIGH-GRADE. | |||
COMMENT: | |||
The tumour stains as follows: | |||
POSITIVE: p16 (strong, diffuse), p53 (strong >85% of tumour). | |||
NEGATIVE: ER, PR. | |||
PROLIFERATION (Ki-67): 80% of the tumour. | |||
</pre> | |||
==See also== | ==See also== | ||
Latest revision as of 14:13, 6 June 2016
| Serous carcinoma of the endometrium | |
|---|---|
| Diagnosis in short | |
 Serous carcinoma of the endometrium. H&E stain. | |
|
| |
| Synonyms | serous endometrial carcinoma, serous carcinoma of the uterus, uterine serous carcinoma, uterine papillary serous carcinoma |
| LM DDx | high-grade endometrioid endometrial carcinoma, clear cell carcinoma of the endometrium,Arias-Stella reaction, serous carcinoma from elsewhere |
| IHC | p16 +ve (strong), p53 +ve usu. (diffuse & strong > 50% or 75% of the tumour), Ki-67 "high", ER -ve, PR -ve |
| Site | endometrium - see endometrial carcinoma |
|
| |
| Clinical history | usu. post-menopausal women |
| Prognosis | moderate-to-poor - dependent on stage |
| Treatment | total hysterectomy + lymph node dissection |
Serous carcinoma of the endometrium is an aggressive type of endometrial carcinoma that typically afflicts post-menopausal women.
It is also known as serous endometrial carcinoma, serous carcinoma of the uterus, uterine serous carcinoma and uterine papillary serous carcinoma.
General
- Arising in the setting of atrophy.
- Usually post-menopausal.
- Precursor lesion: endometrial intraepithelial carcinoma.[1]
- Aggressive behaviour - high probability of disseminated disease.
Gross
- Thin endometrium.
- +/-Polypoid mass.
Microscopic
Features - serous:
- Architecture - classically papillary.
- May be glomeruloid, tubulocystic, solid (uncommon).
- Cytology:
- Columnar or cuboidal cells.
- Moderate to marked nuclear pleomorphism - variation of size, shape and staining.
- Large nuclear size variation between cells often esp. prominent.
- Singular prominent, classically red, nucleolus.
- Moderate to marked nuclear pleomorphism - variation of size, shape and staining.
- Columnar or cuboidal cells.
- +/-Psammoma bodies.
DDx:
- High-grade endometrioid endometrial carcinoma - uncommon, typically younger age.
- Clear cell carcinoma of the endometrium - usually have less nuclear pleomorphism and less mitoses.
- Arias-Stella reaction.
- Metastatic serous carcinoma.
- Endometrium with psammoma bodies - no atypical cells.
Images
Uterine serous carcinoma - low mag. (WC)
Uterine serous carcinoma - high mag. (WC)
IHC
- p16 +ve[2] - should be strong.
- p53 +ve[3] diffuse & strong > 50% or 75% of the tumour - depending on the paper one reads.
- Subset is p53 -ve.
- Ki-67 "high" - no cut-point defined.
- ER often -ve.[4]
- PR often -ve.[4]
High-grade endometrioid carcinoma versus serous carcinoma:[5]
- p53 -ve, PR +ve, PTEN loss -- suggest endometrioid.
- p16 and PTEN superior to ER, PR, and p53.[6]
Notes:
- p16 +ve in tubal metaplasia.[7]
- WT1 usu. -ve -- useful to differentiate from ovarian serous carcinoma.[8]
Sign out
ENDOMETRIUM, BIOPSY: - SEROUS CARCINOMA, HIGH-GRADE. COMMENT: The tumour stains as follows: POSITIVE: p16 (strong, diffuse), p53 (strong >85% of tumour). NEGATIVE: ER, PR. PROLIFERATION (Ki-67): 80% of the tumour.
See also
References
- ↑ Roelofsen, T.; van Kempen, LC.; van der Laak, JA.; van Ham, MA.; Bulten, J.; Massuger, LF. (Mar 2012). "Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion?". Int J Gynecol Cancer 22 (3): 457-64. doi:10.1097/IGC.0b013e3182434a81. PMID 22249577.
- ↑ Chiesa-Vottero, AG.; Malpica, A.; Deavers, MT.; Broaddus, R.; Nuovo, GJ.; Silva, EG. (Jul 2007). "Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.". Int J Gynecol Pathol 26 (3): 328-33. doi:10.1097/01.pgp.0000235065.31301.3e. PMID 17581420.
- ↑ Yemelyanova, A.; Ji, H.; Shih, IeM.; Wang, TL.; Wu, LS.; Ronnett, BM. (Oct 2009). "Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.". Am J Surg Pathol 33 (10): 1504-14. doi:10.1097/PAS.0b013e3181ac35f5. PMID 19623034.
- ↑ 4.0 4.1 Kounelis, S.; Kapranos, N.; Kouri, E.; Coppola, D.; Papadaki, H.; Jones, MW. (Apr 2000). "Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.". Mod Pathol 13 (4): 379-88. doi:10.1038/modpathol.3880062. PMID 10786803.
- ↑ Darvishian, F.; Hummer, AJ.; Thaler, HT.; Bhargava, R.; Linkov, I.; Asher, M.; Soslow, RA. (Dec 2004). "Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.". Am J Surg Pathol 28 (12): 1568-78. PMID 15577675.
- ↑ Alkushi, A.; Köbel, M.; Kalloger, SE.; Gilks, CB. (Jul 2010). "High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.". Int J Gynecol Pathol 29 (4): 343-50. doi:10.1097/PGP.0b013e3181cd6552. PMID 20567148.
- ↑ Horree, N.; Heintz, AP.; Sie-Go, DM.; van Diest, PJ. (2007). "p16 is consistently expressed in endometrial tubal metaplasia.". Cell Oncol 29 (1): 37-45. PMID 17429140.
- ↑ Bárcena, C.; Oliva, E. (Nov 2011). "WT1 expression in the female genital tract.". Adv Anat Pathol 18 (6): 454-65. doi:10.1097/PAP.0b013e318234aaed. PMID 21993272.